Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Nanosonics Limited ( (AU:NAN) ).
Nanosonics Limited announced a change in Director Michael Kavanagh’s interest in securities, specifically acquiring 405,184 Performance Rights under the Nanosonics Equity Plan as part of the company’s long-term incentive (LTI) strategy for 2026. This update reflects the company’s commitment to aligning executive incentives with the long-term strategic and financial goals, indicating a focus on sustainable growth and value delivery for stakeholders.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
More about Nanosonics Limited
Nanosonics Limited operates in the medical technology industry, specializing in infection prevention solutions. The company’s flagship product is a proprietary automated disinfection device used globally in healthcare settings, which supports better clinical outcomes and patient safety.
Average Trading Volume: 592,991
Technical Sentiment Signal: Sell
Current Market Cap: A$1.23B
For an in-depth examination of NAN stock, go to TipRanks’ Overview page.